| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T155 |
0-174 |
Sentence |
denotes |
A potentially more promising strategy would be to create an antibody-like molecule that would bind to the coronavirus itself, rather than shielding cells from being infected. |
| T156 |
175-344 |
Sentence |
denotes |
For this strategy, it is proposed to use a soluble version of the ACE2 receptor that would bind to the S protein of 2019-nCoV thereby neutralizing the virus ( Figure 1). |
| T157 |
345-431 |
Sentence |
denotes |
Again, the research on the SARS virus suggests this strategy is potentially promising. |
| T158 |
432-530 |
Sentence |
denotes |
Soluble ACE2 receptor was demonstrated to block the SARS virus from infecting cells in culture 42. |
| T159 |
531-730 |
Sentence |
denotes |
The reported affinity of soluble ACE2 for the SARS S protein was 1.70 nM, which is comparable to the affinities of monoclonal antibodies 55; it is likely that 2019-nCoV has similar affinity for ACE2. |
| T160 |
731-1047 |
Sentence |
denotes |
In order to use ACE2 as a therapy to treat patients, it would be advisable to convert soluble ACE2 into an immunoadhesin format fused to an immunoglobulin Fc domain (ACE2-Fc), thereby extending the lifespan of the circulating molecule, while also recruiting effector functions of the immune system against the virus. |
| T161 |
1048-1297 |
Sentence |
denotes |
While not tested in an animal model, a previous study demonstrated that an ACE2 extracellular domain fused to the human IgG1 domain (ACE2-NN-Ig) was effective in neutralizing SARS coronavirus in vitro, with a 50% inhibitory concentration of 2 nM 56. |
| T162 |
1298-1416 |
Sentence |
denotes |
This study provides evidence then that ACE2-Fc could similarly inhibit 2019-nCoV in vitro and potentially in patients. |
